CagriSema misses primary endpoint against tirzepatide in head-to-head trial
Novo Nordisk's cagrilintide-semaglutide combination produced weight loss but did not beat Eli Lilly's Zepbound on the trial's primary measure.
MH
By Maren Holt · Senior Reporter, GLP-1
Feb 23 03:00 ETSource: HCPLive
The wire
- 01In a head-to-head trial, CagriSema drove weight loss but failed to achieve the primary endpoint versus tirzepatide, HCPLive reports.
- 02The result bears on how clinicians and operators rank amylin-plus-GLP-1 combinations against tirzepatide as next-generation obesity options arrive.
- 03Full endpoint definitions, dosing and safety data were not detailed in the report; Novo Nordisk's regulatory plans for CagriSema remain to be clarified.
From the source
Read at hcplive.comCagriSema Demonstrates Weight Loss, Fails to Achieve Primary Endpoint Compared to Tirzepatide